International
books
- Međunarodne knjige
1. Mujagić
H, urednik. Imunologija Univerzitet u Tuzli,
2006. Knjiga je temeljna imunologija i u
završnoj je fazi obrade. Sudjeluju autori iz
Bosne, Hrvatske, Slovenije i USA.
Chapters in
international
books -
Poglavlja u međunarodnim knjigama
1. Silobrčić
V, Milas L, Mujagić H. Experimental lung
metastases as a test in tumour immunology. Doll
R, Vodopija I, eds. Host environmental
interactions in the ethyology of cancer in man.
WHO IARC, 1972: 411-417.
2. Curt GA,
Allegra CJ, Fine RL, Mujagić H, Yeh GC, Chabner
BA. Cancer Chemotherapy. Ulmann’s Encyclopedia
of Chemistry. VCH Verlagsgesellschaft, 1986; A5:
1-28.
3. Supko GJ, Puchalski AT, Mujagic
H, Zhu AX, Chabner BA. Clinical Pharmacology of
Anticancer Drugs. Handin RI, Lux SE, Stossel TP,
eds. Handin’s Textbook of Hematology. Lippincott
Williams & Wilkins, 2002: 2095-2133.
4.
Mujagic Hamza: Thalidomide and its analogs.
Harrisons Textbook of Medicine, Harrisons
Oncology. Lippincott Williams and Wilkins, 2006
(in print).
5. Mujagic Hamza: The Taxanes.
Harrisons Textbook of Medicine, Harrisons
Oncology. Lippincott, Williams and Wilkins, 2006
(in print).
Domestic
books
- Domaće knjige
1.
Mujagić H. Praktikum iz Patološke fiziologije.
Banjaluka: Univerzitet u Banjaluci, 1987.
2. Mujagić H. Odabrana poglavlja iz
Patološke fiziologije. Banjaluka: Univerzitet u
Banjaluci, 1988.
3. Nurkić M, Mujagić H.
Imunološki riječnik. Tuzla: Univerzitet u Tuzli,
2001.
Scientific
monographs
- Naučne monografije
1.
Mujagić H, Radovanović Z, Cuculić M, Vujanović
N, Vujić A, Čobić P. SSID-a, Sindrom Stečene
Imunodeficitarnosti, AIDS: Svjetlost- Sarajevo,
1988.
2. Mujagić Hamza, Mujagić Zlata:
Agresivnost tumorske bolesti.
Izdavačko
poduzeće Hamidović, Tuzla, 2003.
Scientific
papers
in
international journals - Naučni
radovi u međunarodnim časopisima
1. Milas L,
Mujagić H. Protection by Corynebacterium parvum
against tumor cells injected intravenously.
Europ J Clin Biol Res 1972; 17: 498-500.
2. Milas L, Mujagić H. The effect of splenectomy
on fibrosarcoma metastases in lungs of mice. Int
J Cancer 1973; 11: 186-190.
3. Mujagić H,
Krušić J, Dešković M, Malenica B. Immunological
reactivity to non-specific antigens in cervical
carcinoma patients. Period Biol 1976; 78:
151-153.
4. Mujagić H, Nola P, Malenica
B, Maričić Ž, Allegretti N. Immunological
reactivity in colorectal carcinoma patients with
special reference to the new classification of
carcinomas of colon and rectum. Period Biol
1976; 78: 153-155.
5. Mujagić H, Mažuran
R, Malenica B, Silobrčić V. Clinical detection
of cellular immunity to melanoma-specific
antigens in men by the monocyte spreading
inhibition test: correlation between in vivo and
in vitro immunological test parameters. Period
Biol 1976; 78: 156-157.
6. Mažuran R,
Mujagić H, Malenica B, Silobrčić V. In vitro
detection of cellular immunity to melanoma
antigens in men by the monocyte spreading
inhibition test. Int J Cancer 1976; 17: 14-20.
7. Rogan J, Mujagić H, Malenica B.
Lymphocyte cytotoxicity to malignant melanoma
and cervical carcinoma cells. Period Biol 1976;
78: 155-156.
8. Malenica B, Mujagić H,
Kolarić K, Radetić M, Maričić Ž, Roguljić A,
Rogan J, Vukas D. BCG immunotherapy in
metatsatic malignant melanoma. Period Biol 1976;
78: 158-159.
9. Mujagić H.The
chemotherapy of gastric carcinoma.The Medical
Herald 1978;14:71-76.
10.Mujagić H,
Kolarić K, Malenica B, Nola P. BCG immunotherapy
in previously treated malignant melanoma
patients. Biomedicine, 1979; 30: 95-102.
11.Mujagić H. Immunotherapy with BCG: an attempt
at standardization of methods based on our
experience and results. Period Biol 1980; 82(2):
195-205.
12.Mujagić H, Dešković M,
Malenica B, Bistrović M, Krušić J. The
significance of tuberculin immunity testing in
cancer patients (invited article). Cell Molec
Biol 1980; 26: (2):111-123.
13.Mujagić H,
Chen SS, Geist R, Occhipinti SJ, Conger BM,
Smith CA, Schuette WH, Shackney SE. Effects of
Vincristine on Cell Survival, Cell Cycle
Progression, and Mitotic Accumulation in
asynchronously growing Sarcoma 180 Cells. Cancer
Res 1983; 43: 3591-3597.
14.Mujagić H,
Conger BM, Smith CE, Occipinti SJ, Shuette WH,
Schackney SE. Schedule dependence of Vincristine
lethality in sarcoma 180 cells following partial
synchronisation with Hydroxiurea. Cancer Res
1983; 43: 3598-3603.
15.Malenica B,
Mujagić H, Popović S, Eljuga D, Allegretti N,
Rogan-Grgas J. Immunocompetence in patients with
malignant melanoma. Period Biol 1983; 16:
351-353.
16.Shuette WH, Chen SS,
Occipinti SJ, Mujagić H, Shackney SE. Automated
radioautographyc grain counting: correction for
grain overlap. Cell Tissue Kinet 1983; 16:
221-227.
17.Mujagić H, Shackney CE, Smith
CE, Chen SS. Quantitative changes in surface
immunoglobulin expression in WEHI-231 lymphoma
cells in relation to their proliferative rate.
Oncology, 1986; 43: 237-242.
18.Krnjajić
N, Jevrić A, Krnjajić Z, Filipović I, Mujagić,
H. Comparison of PGE and PGE2 levels
in pregnant syngeneic Balb/c mice with
transplanted fibrosarcoma. Prog Clin Res 1987;
242: 119-122.
19.Mujagić H, Krnjajić N,
Jevrić A. The levels and relations of
prostaglandins in pregnant and non-pregnant
tumor-bearing mice. J Cancer Res Clin Oncol
1989; 115: 383-387.
20.Mujagić H.
Aggressive chemotherapy and sensitivity
persistance to anticancer drugs.
Ann Paul
Debre Hosp 1990; 41: 7-15.
21.Mujagić H,
Mujagić Z. Detection of pleyotropic drug
resistance by the rapid immunofluorescence assay
of drug effects on cell skeleton. Oncology 1991;
48(3): 202-209.
22.Mujagić H, Blitvić A,
Omeragić F. I can see you but you can not see
me. Updates 1999; 1(3): 4 -11.
23.
Mujagic H, Chabner BA. Thalidomide. MD Vista J
Med 2001; 4: 1-7.
24.Mujagić H, Chabner
BA, Mujagić Z. The mechanisms of action and
potential therapeutic uses of thalidomide. Croat
Med J. 2002; 43(3): 274-285.
25.Mujagić
Z, Mujagić H. Circulating levels of prolactin as
an indicator of effectiveness of therapy in
breast cancer patients. Int J Cancer 2002; Suppl
13: 216.
26.Mujagić Z, Mujagić H.
Prolactin–new tumor marker for breast cancer?
Turk J Biochem 2003; 28 (3): 120-121.
27.Mujagic Z, Mujagic H. Importance of serum
prolactin determinations in metastatic breast
cancer patients. Croat Med J. 2004; 45(2):
176-180.
28.Mujagic Z, Mujagic H. The
relationship of circulating prolactin levels to
the size of primary tumor in breast cancer
patients. Turk J Biochem. 2004; 29 (4): 277-281.
29.Pranjic N, Mujagic H. Gasoline sniffing
and lead toxicity in workers at gasoline
stations. J Occup Env Med. 1998; 40(11):
1024-1029.
Scientific
papers
in
proceedings of international
conferences
and
symposia
Naučni radovi u zbornicima međunarodnih kongresa
i simpozija
1.Mujagić H,
Kolarić K. The value of immunological skin tests
in Oncology. Book of abstracts of the Sec Int
Cong Bulgarian Oncol, Varna, 1970. p.104.
2.Mažuran R, Mujagić H, Silobrčić V.
Cellular immunity in vitro to melanoma-specific
antigens in men detected by the macrophage
spreading inhibition test. Book of abstracts of
the 3th Europ Immunol Meeting,
Amsterdam, 1975. p. 125.
3.Mujagić H,
Milas L, Allegretti N, Nola P, Malenica B,
Maričić Ž. Immunological reactivity in
colorectal carcinoma patients with special
reference to the new T-S classification of
carcinomas on the colon and rectum. Book of
abstracts of the Tenth Int Congr Gastroenter,
Budapest, 1976. p. 412.
4.Mujagić H,
Dešković M, Malenica B. Tuberculin immunity in
cancer patients; clinical and prognostic
significance. Bok of abstracts of the 12th
Int Cancer Congr, Buenos Aires, 1978. p. 126.
5.Mujagić H, Kolarić K, Nola P.
Immunological status in malignant melanoma
patients. Book of abstracts of the 12th
Int Cancer Congr, Buenos Aires, 1978. p. 188.
6.Mujagić H. Clinical immunological status
in malignant melanoma patients. Book of
abstracts of the 6th Europ
Immunol Meeting, Paris, 1980. p. 188.
7.Mujagić H, Smith CE, Shuette WH, Shackney SE.
The cell tubulin content frequency histogram
obtained by flow cytometry in sarcoma 180 cells
in vitro. Proc Am Assoc Cancer Res, Denver,
1982. p. 105.
8.Chen SS, Occipinti SJ,
Mujagić H, Smith CE, Shuette WH, Shackney SE.
Multiparameter radiographic image abalysis
studies in human lymphomas. Proc Am Assoc Clin
Oncol, Denver, 1982. p. 107.
9.Conger B,
Occipinti SJ, Mujagić H, Smith CE, Shuette WH,
Shackney SE. Studies on lethal and sublethal
effects of Vincristine on sarcoma 180 cells in
vitro. Proc Am Soc Cell Kin, Houston, 1982. p.
32.
10.Radičević N, Mujagić H. The
effect of methylnitrosourea (MNU) on the growth
of transplanted methylcholanthrene-induced
fibrosarcoma in Balb/c mice. Book of abstracts
of the Second World Congress of Pharmacology,
Tokyo, 1982. p. 103.
11.Radičević N,
Mujagić H. The relationship of macrophage
spreading inhibition (MSI) with tumor growth and
non-specific immunotherapy. Book of abstracts of
the 2th World Cong Pharmacol,
Tokyo, 1982: Abs.10.5.56.
12.Mujagić H.
Tumor-directed immune reactivity in malignant
melanoma patients. Book of abstracts of the 2th
World Congr Pharmacol, Tokyo, 1982: Abs.10.5.51.
13.Mujagić H, Smith CE, Occipinti S, Shuette
WH, Shackney SE. The quantitative changes in
immunoglobulin contents on the surface of
WEHI-231 lymphoma cells in relation to their
proliferative rate. Proc Am Assoc Cancer Res,
Atlanta, 1983. p. 32.
14.Curt GA, Bailey
BD, Mujagić H, Chabner BA. Pleiotropic drug
resistance in MCF-7 human breast carcinoma cell
line. Proc Am Assoc Cancer Res, Houston, 1984.
p. 104.
15.Petronijević S, Krnjajić N,
Jevrić A, Mujagić H. PGF2 alfa
levels in pregnant syngeneic Balb/c mice with
transplanted methylcholanthrene fibrosarcoma.
Joint Meeting Jugosl Finish Pharm, Dubrovnik,
1986. p. 66.
16.Krnjajić N, Petronijević
S, Jevrić A, Krnjajić Z, Mujagić H. PGFalfa and
PGF2alfa levels in pregnant syngeneic
Balb/c mice with transplanted fibrosarcoma. Book
of abstracts of the 6th Conf
Prostagl Rel Comp, Florence, 1986. p. 206.
17.Krnjaić N, Jevrić A, Mujagić H, Krnjaić
Z. The relationship between the levels of PGE1
and PGE2 and macrophage
spreading inhibition in tumor bearing mice. 3th
Int Symp Prostagland, Bad Ischly, 1986. p. 17.
18.Mujagić Z, Mujagić H. Diagnostic and
Prognostic Usefulness of Prolactin (PRL) in
Breast Cancer (BC). Proc. ASCO, San Francisco,
2001. p. 20 (43b).
19.Mujagić Z, Mujagić
H. Prognostic significance of circulating levels
of prolactin (PRL) in metastatic breast cancer
(MBC). Proc ASCO, Chicago, 2003. p. 22(49).
20.Mujagic Z, Cicko E, Mujagic H.
Circulating levels of prolactin before, during
and after surgery in patients under total
intravenous and general balanced anesthesia.
Proceedings of IMMPC-2, Antalya, Turkey 2004.
21.Mujagic Z, Mujagic H. The relationship of
circulating prolactin levels to the size of
primary tumor in breast cancer patients.
Proceedings of the 4th
European Conference: «Perspectives in
breast cancer», Madrid Spain 2004. p. 22.
Scientific
articles
in
national journals
- Naučni radovi u domaćim časopisima
1.Mujagić H, Malenica B, Nola P, Maričić Ž,
Kolarić K. BCG immunotherapy applied after
surgery in malignant melanoma patients. The Med
Rev, Galenika 1976; 16: 42-48.
2.Mujagić
H, Roth A, Smudj K, Malenica B, Juzbašić S.
Immunotherapy and chemotherapy in the treatment
of advanced osteosarcoma–A case report. Iugosl
Orthopaed Acta 1977; 2: 209-213.
3.Mujagić H. The possibilities of immunotherapy
of malignant tumors in men. Med Arch 1978; 32:
43-49.
4.Mujagić H. The monitoring of
lymphocyte blast specific and non-specific
transformation in malignant melanoma patients
and the possibilities of clinical utilisation of
results. Radiol Jugosl 1978; 12: 794-804.
5.Krnjajić N, Jevrić A, Petronijević S,
Krnjajić Z, Mujagić H. PGE2 levels in
pregnant syngeneic BaLb/c mice with transplanted
methylcholanthrene fibrosarcoma. Yugoslav
Physiol Pharmacol Acta, 1985; 21 (3): 191-192.
6.Pertonijević S, Krnjaić N, Jevrić A,
Mujagić H. PGF2 alfa levels in
pregnant syngeneic BALB/c mice with transplanted
methylcholantrene fibrosarcoma. Iugoslav Physiol
Pharmacol Acta 1985; 21(suppl.3)p. 66.
7.Mujagić H. Morphological changes in cell
skeleton caused by anticancer drugs. Inform
karcinog 1990; 7: 9-23.
8.Pjanić A,
Unčanin D, Sarajlić O, Abaspahić E, Mujagić H.
Detection of cellular immunity in
gastrointestinal carcinoma patients by the
leucocyte adherence inhibition assay. Scripta
Medica, 1991; 22: 10-16.
9.Šabanović Z,
Mujagić H, Bazrdjanović M. Quality of medical
records as a basis for DRG classification in the
health care system in Bosnia and Hercegovina.
Med Arch 1999; 53 (suppl 3): 61-64.
10.Ljuca Dž, Fatušić Z, Mujagić H, Ljuca F,
Alispahić N. Precarcinoma and early
carcinomatous lesions in the uterine cervix and
the use of oral contraceptives. Med Arch 2000;
54 (2): 71-73.
11.Pranjić N, Mujagić H,
Nurkić M, Karamehić J, Pavlović S. Assessment of
health effects in workers at gasoline stations.
Bosnian Journal of Basic Medical Sciences 2002,
2 (1-2): 35-45.
12.Pranjić N, Mujagić H,
Pavlović S. Inhalation of gasoline and damage to
health in workers at gasoline stations. Med Arch
2003; 57 (1): 17-20.
13.Mujagić H,
Prnjavorac B, Mujagić Z, Festa G. Alcohol in
alcoholic liver disease is a causative factor
for development of allergic skin manifestations.
Med Arch 2003; 57 (5-6): 273-278.
14.Mujagić Z, Mujagić H. Diagnostic usefulness
of serum carcinoembryonic antigen determinations
in breast cancer patients. Bosnian Journal of
Basic Medical Sciences 2003; 3 (2): 30-34.
15.Mujagić Z, Mujagić H, Prnjavorac B.
Circulating levels of prolactin in breast cancer
patients. Med Arch 2005;59 (1):33-35.
16.Mujagić Z, Mujagić H, Prnjavorac B. The
relationship between carcinoembryonic antigen (CEA)
levels and parameters of primary tumor and
metastases in breast cancer patients. Med Arch
2004;58 (1): 23-26.
17.Mujagić Z, Mujagić
H, Prnjavorac B. The relationship between
circulating carcinoembryonic antigen (CEA)
levels and parameters of primary tumor and
metastases in breast cancer patients. Med Arch
2004; 58 (1): 23-26
Znanstveni
radovi u zbornicima domaćih kongresa i simpozija
1.Mujagić H, Milas L. The effect of
Corynebacterium parvum on the growth of
experimental metastases of fibrosarcoma in the
lungs of C57BL mice. Proc
Jugosl Immunol Soc, Beograd 1971. p. 68.
2. Milas L, Mujagić H. The growth of
experimental metastases of fibrosarcoma in the
lungs of splenectomised C57BL mice. Proc Jugosl
Immunol Soc, Beograd 1971. p. 67.
3.Mujagić H, Milas L, Malenica B, Jurčić D,
Krušić J. Immunological reactivity in patients
with rectal carcinoma. Book of abstracts of the
Sixth Congr Jugosl Oncol, Sarajevo, 1975. p. 77.
4.Malenica B, Mujagić H, Radetić M,
Maričić Ž, Roguljić A, Vukas D. BCG
immunostimulation in malignant metastatic
melanoma patients. Book of abstracts of the
Sixth Congr Jugosl Oncol, Sarajevo, 1975. p. 30.
5.Mujagić H, Krušić J, Dešković M,
Malenica B. Imunološka reaktivnost nespecifične
antigene u bolesnica s karcinomom cerviksa. Book
of abstracts of the Sixth Congr Jugosl
Oncol,Sarajevo, 1975: 35.
6.Mujagić H,
Mažuran R, Malenica B, Silobrčić V. Klinička
detekcija celularne imunosti na melanomske
antigene in vitro testom inhibicije širenja
monocita. Book of abstracts of the Sixth Congr
Jugosl Oncol, Sarajevo, 1975. p. 36.
7.Rogan J, Mujagić H, Malenica B. Citotoksičnost
limfocita bolesnika s melanomom. Book of
abstracts of the Sixth Congr Jugosl Oncol,
Sarajevo, 1975. p. 49.
8.Mujagić H,
Kolarić K, Malenica B, Popović Š, Maričić Ž.
BCG-imunostimulacija bolesnika s malignim
melanomom. Book of abstracts of the Sixth Congr
Jugosl Oncol, Sarajevo, 1975. p. 80.
9.Mujagić H, Djordjević J, Lovrinčević A,
Starović B. The extent of disease and frequency
of localisation of metastases in malignant
melanoma patients. Book of Abstracts of the Int
Jugosl Radiol Congr, Novi Sad, 1980. p. 39.
10.Mujagić H, Malenica B, Nola P.
Immunological Prophyle in malignant melanoma
patients. Book of abstracts of the Sixth Int
Cong Iugosl Oncol, Ljubljana, 1980. p.43.
11.Hadžiomerović V, Mujagić H, Bušić I.
Immunological characteristics of patients with
carcinomas of the head and neck. Book of
abstracts of the Sec Int Congr ENT Soc, Niš,
1980. p. 21.
12. Hadžiomerović V,
Mujagić H. The combination of Doxorubicin and
radiotherapy in the treatment of patients with
carcinoma of head and neck. Book of abstracts of
the Sixth Int Congr Yugosl Oncol, Ljubljana,
1980. p. 44.
13. Krnjajić A, Jevrić A,
Petronijević S, Mujagić H, Krnjajić Z. PGE2
levels in pregnant BaLb/c mice with transplanted
methylcholanthrene Fibrosarcoma. Book of
abstracts of the Ninth Congr Yugosl Pharm Soc,
Beograd, 1985: p. 193.
14.Krnjaić N,
Jevrić A, Mujagić H, Petronijević S, Krnjaić Z.
PGE1 levels in pregnant syngeneic
BALB/c mice with transplanted methylcholantrene
fibrosarcoma. Book of abstracts of the 13th
Congress of UYPS, Skopje, 1985: Abs. 291.
15.Mujagić H. Liječenje bolesnika sa
malignim tumorom u uvjetima promijenjene
ekološke sredine. Zbornik radova Simpozija o
životnoj sredini, Novi Sad, 1990. p. 17.
16.Mujagić Z, Mujagić H. The relationship
between smoking habits and serum prolactin
levels in breast cancer patients. Proceedings of
the First Bosnia and Herzegovina Congress of
Occupational Medicine with International
Participations, Tuzla, 2003. p. 242.
17.Mujagić Z, Mujagić H. Circulating levels of
prolactin in relation to age in breast cancer
patients. Proceedings of the First Bosnia and
Herzegovina Congress of Occupational Medicine
with International Participations, Tuzla, 2003.
p. 256.
Prof. Dr. med. Sc., Hamza Mujagic
Massachusetts General Hospital and Harvard University, Boston,
USA
